Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot study.
This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.
Mueller
Andreas
A
Department of Obstetrics and Gynecology, Erlangen University Hospital, Erlangen, Germany. andreas.mueller@uk.uni-erlangen.de
Maltaris
Theodoros
T
Häberle
Lothar
L
Hoffmann
Inge
I
Beckmann
Matthias W
MW
Dittrich
Ralf
R
D004958:Estradiol / Q000097:blood; D005260:Female; D043373:Follicle Stimulating Hormone, Human / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D017273:Goserelin / Q000627:therapeutic use*; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010865:Pilot Projects; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014189:Transsexualism / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D043373:Follicle Stimulating Hormone, Human; D006727:Hormone Antagonists; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D004958:Estradiol; D007986:Luteinizing Hormone; C062876:cetrorelix